Advertisement

The Impact of Pharmacist-Based Services Across the Spectrum of Outpatient Heart Failure Therapy

  • Lucianne M. West
  • J. Bradley Williams
  • Kathleen D. FaulkenbergEmail author
Heart Failure (W Tang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Heart Failure

Abstract

Purpose of review

A multidisciplinary approach is vital to reduce mortality and hospitalizations in patients with heart failure. As members of the multidisciplinary team, pharmacists are uniquely positioned to care for patients across the spectrum of heart failure. This comprehensive review explores the different facets in which pharmacists can be utilized to impact the care for patients with heart failure, including those with cardiac transplant and left ventricular assist devices (LVADs), in the outpatient setting.

Recent findings

Pharmacists can see heart failure patients in a variety of settings to reduce drug therapy–related issues, increase use of guideline-directed medical therapy (GDMT), and reduce hospitalizations. Although there is limited data available, pharmacists have also been described in aiding the therapeutic drug monitoring of warfarin for patients with LVADs and immunosuppression agents in the transplant population.

Summary

Through collaborative practice agreements, pharmacists can provide progressive services such as titration of GDMT and lab monitoring, in addition to medication reconciliation, education, and review for potential drug-related problems. Pharmacists can increase access to patient care by providing services through distance-visits, shared medical appointments, and home visits.

Keywords

Heart failure Pharmacist-based services Outpatient therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mozaffarian. Heart Disease and stroke statistics-2016 update: a report from the American Heart Association (vol 133, pg e38, 2016). Circulation. 2016;133(15):E599.Google Scholar
  2. 2.
    Page RL. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association (vol 134, pg e32, 2016). Circulation. 2016;134(12):E261.Google Scholar
  3. 3.
    Yancy CW, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.PubMedGoogle Scholar
  4. 4.
    •• Milfred-Laforest SK, et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Card Fail. 2013;19(5):354–69. First opinion paper describing the benefits of clinical pharmacy services in patients with heart failure.PubMedGoogle Scholar
  5. 5.
    •• Dunn SP, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66(19):2129–39. Describes the training and qualifications of clinical pharmacist to provide care for patients with cardiovascular diseases. Provides a systematic review of summarizing pharmacy services provided to patients with cardiovascular disease.PubMedGoogle Scholar
  6. 6.
    Lenander C, Elfsson B, Danielsson B, Midlöv P, Hasselström J. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care. 2014;32(4):180–6.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, Havranek EP, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005;165(18):2069–76.PubMedGoogle Scholar
  8. 8.
    Dempsey JT, Matta LS, Carter DM, Stevens CA, Stevenson LW, Desai AS, et al. Assessment of drug therapy-related issues in an outpatient heart failure population and the potential impact of pharmacist-driven intervention. J Pharm Pract. 2017;30(3):318–23.PubMedGoogle Scholar
  9. 9.
    Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17(3):217–23.PubMedGoogle Scholar
  10. 10.
    Yates L, Valente, M, Wadsworth C. Evaluation of pharmacist medication review service in an outpatient Heart Failure Clinic. J Pharm Pract. 2019;897190019842696.Google Scholar
  11. 11.
    Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med. 2007;146(10):714–25.PubMedGoogle Scholar
  12. 12.
    Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy. 1999;19(7):860–9.PubMedGoogle Scholar
  13. 13.
    Bucci C, et al. Pharmacist’s contribution in a heart function clinic: patient perception and medication appropriateness. Can J Cardiol. 2003;19(4):391–6.PubMedGoogle Scholar
  14. 14.
    Dempsey J, Gillis C, Sibicky S, Matta L, MacRae C, Kirshenbaum J, et al. Evaluation of a transitional care pharmacist intervention in a high-risk cardiovascular patient population. Am J Health Syst Pharm. 2018;75(17 Supplement 3):S63–71.PubMedGoogle Scholar
  15. 15.
    Singh-Franco D, Li L, Hannah S, Diamond M. Role of clinical pharmacist in a heart failure clinic. Hosp Pharm. 2005;40(10):890–6.Google Scholar
  16. 16.
    Elman S, Zaiken K. Improving performance of an accountable care organization on a quality measure assessing beta-blocker use in systolic heart failure. Am J Health Syst Pharm. 2016;73(17 Suppl 4):S121–5.PubMedGoogle Scholar
  17. 17.
    Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail. 2003;9(5):404–11.PubMedGoogle Scholar
  18. 18.
    Turner CJ, Parfrey P, Ryan K, Miller R, Brown A. Community pharmacist outreach program directed at physicians treating congestive heart failure. Am J Health Syst Pharm. 2000;57(8):747–52.PubMedGoogle Scholar
  19. 19.
    Ziman ME, Bui HT, Smith CS, Tsukiji LA, Asmatey VM, Chu SB, et al. The pharmacists’ role in improving guideline compliance for thyroid function testing in patients with heart failure. J Pharm Pract. 2012;25(2):195–200.PubMedGoogle Scholar
  20. 20.
    Bleske BE, Dillman NO, Cornelius D, Ward JK, Burson SC, Diez HL, et al. Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc (2003). 2014;54(6):634–41.Google Scholar
  21. 21.
    Lowrie R, Johansson L, Forsyth P, Bryce SL, McKellar S, Fitzgerald N. Experiences of a community pharmacy service to support adherence and self-management in chronic heart failure. Int J Clin Pharm. 2014;36(1):154–62.PubMedGoogle Scholar
  22. 22.
    Laufs U, Griese-Mammen N, Krueger K, Wachter A, Anker SD, Koehler F, et al. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. Eur J Heart Fail. 2018;20(9):1350–9.PubMedGoogle Scholar
  23. 23.
    • Schulz M, Griese-Mammen N, Anker SD, Koehler F, Ihle P, Ruckes C, et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail. 2019Recent large randomized control trial demonstrating the positive impact of pharmacist in the community setting on medication adherence.Google Scholar
  24. 24.
    Yancy CW, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.PubMedGoogle Scholar
  25. 25.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Am J Cardiol. 2008;102(11):1524–9.PubMedGoogle Scholar
  26. 26.
    Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011;161(6):1024–30 e3.PubMedGoogle Scholar
  27. 27.
    Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–66.PubMedGoogle Scholar
  28. 28.
    Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7(4):350–8.PubMedGoogle Scholar
  29. 29.
    Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159(16):1939–45.PubMedGoogle Scholar
  30. 30.
    Al-Bawardy R, et al. Heart failure postdischarge clinic: a pharmacist-led approach to reduce readmissions. Curr Probl Cardiol. 2019.Google Scholar
  31. 31.
    • Bhat S, et al. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52(8):724–32 Study describes the workflow of a pharmacist-led, protocol-driven, medication titration clinic in a HFrEF, non-veteran population.PubMedGoogle Scholar
  32. 32.
    Donaho EK, Hall AC, Gass JA, Elayda MA, Lee VV, Paire S, et al. Protocol-driven allied health post-discharge transition clinic to reduce hospital readmissions in heart failure. J Am Heart Assoc. 2015;4(12).Google Scholar
  33. 33.
    • Hale GM, et al. Impact of a pharmacist-managed heart failure postdischarge (bridge) clinic for veterans. Ann Pharmacother. 2017;51(7):555–62. Recent large analysis that describes the benefits of medication review, education, and optimization in both HFrEF and HFpEF veterans.PubMedGoogle Scholar
  34. 34.
    Jackevicius CA, de Leon NK, Lu L, Chang DS, Warner AL, Mody FV. Impact of a multidisciplinary heart failure post-hospitalization program on heart failure readmission rates. Ann Pharmacother. 2015;49(11):1189–96.PubMedGoogle Scholar
  35. 35.
    Jain A, Mills P, Nunn LM, Butler J, Luddington L, Ross V, et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail. 2005;7(3):405–10.PubMedGoogle Scholar
  36. 36.
    Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33(3):314–24.PubMedGoogle Scholar
  37. 37.
    Martinez AS, Saef J, Paszczuk A, Bhatt-Chugani H. Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm. 2013;70(12):1070–6.PubMedGoogle Scholar
  38. 38.
    Milfred-LaForest SK, Gee JA, Pugacz AM, Piña IL, Hoover DM, Wenzell RC, et al. Heart failure transitions of care: a pharmacist-led post-discharge pilot experience. Prog Cardiovasc Dis. 2017;60(2):249–58.PubMedGoogle Scholar
  39. 39.
    Noschese LA, et al. The pharmacist’s role in medication optimization for patients with chronic heart failure. Fed Pract. 2017;34(Suppl 10):S10–5.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Pogge EK, Davis LE. Evaluating the safety and tolerability of sacubitril/valsartan for HFrEF managed within a pharmacist clinic. Am J Cardiovasc Drugs. 2018;18(2):143–51.PubMedGoogle Scholar
  41. 41.
    Schumacher C, Moaddab G, Colbert M, Kliethermes MA. The effect of clinical pharmacists on readmission rates of heart failure patients in the accountable care environment. J Manag Care Spec Pharm. 2018;24(8):795–9.PubMedGoogle Scholar
  42. 42.
    Albert NM, Barnason S, Deswal A, Hernandez A, Kociol R, Lee E, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail. 2015;8(2):384–409.PubMedGoogle Scholar
  43. 43.
    Alexander E, Butler CD, Darr A, Jenkins MT, Long RD, Shipman CJ, et al. ASHP statement on telepharmacy. Am J Health Syst Pharm. 2017;74(9):e236–41.PubMedGoogle Scholar
  44. 44.
    Lopez Cabezas C, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs. regular follow-up in patients with heart failure. Farm Hosp. 2006;30(6):328–42.PubMedGoogle Scholar
  45. 45.
    McKinley D, Moye-Dickerson P, Davis S, Akil A. Impact of a pharmacist-led intervention on 30-day readmission and assessment of factors predictive of readmission in African American men with heart failure. Am J Mens Health. 2019;13(1):1557988318814295.PubMedGoogle Scholar
  46. 46.
    Moye PM, Chu PS, Pounds T, Thurston MM. Impact of a pharmacy team-led intervention program on the readmission rate of elderly patients with heart failure. Am J Health Syst Pharm. 2018;75(4):183–90.PubMedGoogle Scholar
  47. 47.
    Murphy JA, Schroeder MN, Rarus RE, Yakubu I, McKee SOP, Martin SJ. Implementation of a cardiac transitions of care pilot program: a prospective study of inpatient and outpatient clinical pharmacy services for patients with heart failure exacerbation or acute myocardial infarction. J Pharm Pract. 2019;32(1):68–76.PubMedGoogle Scholar
  48. 48.
    Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health Syst Pharm. 1999;56(13):1339–42.PubMedGoogle Scholar
  49. 49.
    Salas CM, Miyares MA. Implementing a pharmacy resident run transition of care service for heart failure patients: effect on readmission rates. Am J Health Syst Pharm. 2015;72(11 Suppl 1):S43–7.PubMedGoogle Scholar
  50. 50.
    Truong JT, Backes AC. The impact of a continuum of care resident pharmacist on heart failure readmissions and discharge instructions at a community hospital. SAGE Open Med. 2015;3:2050312115577986.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Hayhoe B, Verma A, Kumar S. Shared medical appointments. BMJ. 2017;358:j4034.PubMedGoogle Scholar
  52. 52.
    Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37(6):801–12.PubMedGoogle Scholar
  53. 53.
    Kirsh S, Watts S, Pascuzzi K, O'Day ME, Davidson D, Strauss G, et al. Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. Qual Saf Health Care. 2007;16(5):349–53.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Edelman D, et al. In Shared medical appointments for chronic medical conditions: a systematic review. Washington (DC); 2012.Google Scholar
  55. 55.
    Singrey AM, Mehta BH, Casper KA. Management of heart failure patients through integrative medical group visits. Am J Health Syst Pharm. 2015;72(5):349–51.PubMedGoogle Scholar
  56. 56.
    Wu WC, Parent M, Dev S, Hearns R, Taveira TH, Cohen L, et al. Group medical visits after heart failure hospitalization: study protocol for a randomized-controlled trial. Contemp Clin Trials. 2018;71:140–5.PubMedGoogle Scholar
  57. 57.
    Barker A, Barlis P, Berlowitz D, Page K, Jackson B, Lim WK. Pharmacist directed home medication reviews in patients with chronic heart failure: a randomised clinical trial. Int J Cardiol. 2012;159(2):139–43.PubMedGoogle Scholar
  58. 58.
    Boykin A, Wright D, Stevens L, Gardner L. Interprofessional care collaboration for patients with heart failure. Am J Health Syst Pharm. 2018;75(1):e45–9.PubMedGoogle Scholar
  59. 59.
    Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith R, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. BMJ. 2007;334(7603):1098.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Kalista T, Lemay V, Cohen L. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure. J Am Pharm Assoc (2003). 2015;55(4):438–42.Google Scholar
  61. 61.
    Lee VW, Choi LM, Wong WJ, Chung HW, Ng CK, Cheng FW. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC Cardiovasc Disord. 2015;15:178.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Roughead EE, Barratt JD, Ramsay E, Pratt N, Ryan P, Peck R, et al. The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. Circ Heart Fail. 2009;2(5):424–8.PubMedGoogle Scholar
  63. 63.
    Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998;158(10):1067–72.PubMedGoogle Scholar
  64. 64.
    Triller DM, Hamilton RA. Effect of pharmaceutical care services on outcomes for home care patients with heart failure. Am J Health Syst Pharm. 2007;64(21):2244–9.PubMedGoogle Scholar
  65. 65.
    Department for Health and Human Services, Centers for Medicare & Medicaid Services. Medicare program; hospital conditions of participation: requirements for approval and reapproval of transplant centers to prefrom organ transplants. Fed Regist. 2007;72(61):15198–280.Google Scholar
  66. 66.
    United Network for Organ Sharing. 2015. Appendix D of UNOS bylaws: changes in key transplant program personnel. https://unos.org/wp-content/uploads/unos/UNOS_Bylaws.pdf. Accessed 29 May 2019.
  67. 67.
    Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, et al. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team. Am J Transplant. 2011;11(8):1576–83.PubMedGoogle Scholar
  68. 68.
    Gellatly RMLC. The addition of a specialist pharmacist to heart transplant and ventricular assist device clinics-early TRANDS in patient care [abstract]. J Heart Lung Transplant. 2015;34:S240–1.Google Scholar
  69. 69.
    Thrall SA, Fominaya CE, Chiasson JM, Castle S, Taber DJ. Improvement in immunosuppression therapy monitoring in organ transplant recipients. Am J Health Syst Pharm. 2017;74(17 Supplement 3):S67–74.PubMedGoogle Scholar
  70. 70.
    Wang N, Athans V, Neuner E, Bollinger J, Spinner M, Brizendine K. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients. Transpl Infect Dis. 2018;20(6):e12991.PubMedGoogle Scholar
  71. 71.
    Bissonnette J, Woodend K, Davies B, Stacey D, Knoll GA. Evaluation of a collaborative chronic care approach to improve outcomes in kidney transplant recipients. Clin Transpl. 2013;27(2):232–8.Google Scholar
  72. 72.
    Cajita MI, Baumgartner E, Berben L, Denhaerynck K, Helmy R, Schönfeld S, et al. Heart transplant centers with multidisciplinary team show a higher level of chronic illness management - findings from the international BRIGHT study. Heart Lung. 2017;46(5):351–6.PubMedGoogle Scholar
  73. 73.
    De Geest S, et al. Chronic illness management as an innovative pathway for enhancing long-term survival in transplantation. Am J Transplant. 2011;11(10):2262–3.PubMedGoogle Scholar
  74. 74.
    Bishop MA, Streiff MB, Ensor CR, Tedford RJ, Russell SD, Ross PA. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J. 2014;60(2):193–8.PubMedGoogle Scholar
  75. 75.
    Kuyumjian YM, Miyares MA, Leverock J, Chaparro S, Baker WL, Jennings DL. A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices. Int J Cardiol. 2016;218:118–9.PubMedGoogle Scholar
  76. 76.
    Borden M, Kiernan MS, Pham DT, DeNofrio D, Sylvia L. Bridging with half-therapeutic dose enoxaparin in outpatients with left ventricular assist devices and sub-therapeutic international normalized ratios. J Heart Lung Transplant. 2015;34(6):860–2.PubMedGoogle Scholar
  77. 77.
    American Pharmacists Association, F. and A. American Pharmacists. Consortium recommendations for advancing pharmacists’ patient care services and collaborative practice agreements. J Am Pharm Assoc (2003). 2013;53(2):e132–41.Google Scholar
  78. 78.
    •• Centers for Disease Control and Prevention. Advancing team-based care through collaborative practice agreement: a resource and implementation guide for adding pharmacists to the care team. Atlanta: Centers for Disease Control and Prevention, U.S. Department fo Health and Human Services; 2017. This guide provides an outline of the steps needed to incorporate pharmacists into the ambulatory care setting through the use of collaborative practice agreements.Google Scholar
  79. 79.
    Hazlet TK, Karwaki TE, Downing DF. Pathway to pharmacist medical provider status in Washington State. J Am Pharm Assoc (2003). 2017;57(1):116–9.Google Scholar
  80. 80.
    Hawes EM, Misita C, Burkhart JI, McKnight L, Deyo ZM, Lee RA, et al. Prescribing pharmacists in the ambulatory care setting: experience at the University of North Carolina Medical Center. Am J Health Syst Pharm. 2016;73(18):1425–33.PubMedGoogle Scholar
  81. 81.
    Maldonado AQ, Seiger TC, Urann CL, McCleary JA, Goroski AL, Ojogho ON. Billing for outpatient transplant pharmacy services. Am J Health Syst Pharm. 2012;69(2):144–7.PubMedGoogle Scholar
  82. 82.
    Department for Health and Human Services, Centers for Medicare & Medicaid Services. Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Procurement Organization Reporting and Communication; Transplant Outcome Measures and Documentation Requirements; Electronic Health Record (EHR) Incentive Programs; Payment to Nonexcepted Off-Campus ProviderBased Department of a Hospital; Hospital Value-Based Purchasing (VBP) Program; Establishment of payment rates under the medicare physician fee schedule for nonexcepted items and services furnished by an off-campus provider-based Department of a Hospital Federal Register. 2016;81(219):79562–79892.Google Scholar
  83. 83.
    Sachdev GP. Billing for pharmacists’ services provided to ambulatory care patients. Am J Health Syst Pharm. 2012;69(2):105.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Lucianne M. West
    • 1
  • J. Bradley Williams
    • 1
  • Kathleen D. Faulkenberg
    • 1
    Email author
  1. 1.Department of PharmacyCleveland ClinicClevelandUSA

Personalised recommendations